Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- 2016-NIV-0677 A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer No ClinicalTrials.gov identifier reported
- 2016-NIV-0686 Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Pts with Extensive-Disease SCLC No ClinicalTrials.gov identifier reported
- 2016-NIV-0691 Adjuvant Nivolumab in High-Risk Patients with Stage II melanoma No ClinicalTrials.gov identifier reported
- 2016-NIV-0692 Ph1/2 Stdy of Sfty/Efficacy Using Trabectedin, Ipilimumab and Nivo Triple Therapy as 1st Ln Treatment of Adv Soft Tissue Sarcoma No ClinicalTrials.gov identifier reported
- 2016-NIV-0699 Phase II Study of IMRT Re-Irradiation with concurrent adjuvant Nivolumab in locally recurrent curable SCCHN No ClinicalTrials.gov identifier reported
- 2016-NIV-0699 Phase II Study of IMRT Re-Irradiation with concurrent/adjuvant Nivolumab in locally recurrent curable SCCHN No ClinicalTrials.gov identifier reported
- 2016-NIV-0704 Checkpoint blockade after Reolysin infection in Myeloma No ClinicalTrials.gov identifier reported
- 2016-NIV-0707 Ph II Neoadj trial of Nivo in comb with HF10 Oncolytic Viral Therapy in Res Stage IIIB, IIIC, IVM1a Mel(Neo-NivoHF10) No ClinicalTrials.gov identifier reported
- 2016-NIV-0717 A randomized phase II trial of carboplatin plus minus nivolumab in first- or second-line metastatic triple-negative breast cancer No ClinicalTrials.gov identifier reported
- 2016-NIV-0719 A PhII 2 Arm Rand Stdy of Nivo in combo w either Gemcitabine Cisplating or Ipi 1st Line Pts with adv Unresectable Biliary Tract Cancer No ClinicalTrials.gov identifier reported
- 2016-NIV-0719 A PhII 2 Arm Rand Stdy of Nivo in combo w either Gemcitabine/Cisplating or Ipi 1st Line Pts with adv Unresectable Biliary Tract Cancer No ClinicalTrials.gov identifier reported
- 2016-NIV-0725 Rand ph2 trial of gem carbo nivo vs gem oxal nivo in cisplatin-ineligible pts with metastatic urothelial cancer No ClinicalTrials.gov identifier reported
- 2016-NIV-0729 Induction Nivolumab Plus Weekly Carboplatin Paclitaxel in Resectable Head and Neck Cancer No ClinicalTrials.gov identifier reported
- 2016-NIV-0740 Nivo immuno w rad therapy and androgen deprivation therapy in management of Gleason Gr 5 locally advanced prostate cancer No ClinicalTrials.gov identifier reported
- 2016-NIV-0741 phII trial of nivolumab, ipilimumab, and short course radiotherapy in newly diagnosed glioblastoma pats w unmethylated MGMT promoter No ClinicalTrials.gov identifier reported
- 2016-Nivo-0519 Phase II study of combination of nivolumab and ibrutinib in patients with relapsed or refractory central nervous system diffuse large B-cell lymphoma No ClinicalTrials.gov identifier reported
- 2016-NPS-0267 Evaluation of Rheumatoid Arthritis Disease Burden in Routine Care No ClinicalTrials.gov identifier reported
- 2016-ORE-0064 Abatacept for Graft Versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease a Sickle Transplant Alliance for Research Trial No ClinicalTrials.gov identifier reported
- 2016-ORE-0067 Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Diseases No ClinicalTrials.gov identifier reported
- 2016-ORE-0075 A randomized controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome No ClinicalTrials.gov identifier reported
- 2016-ORE-0087 Phase II study of targeting CD28 in multiple myeloma with abatecept (CTLA4-Ig) to overcome resistance to chemotherapy No ClinicalTrials.gov identifier reported
- 2016-ORE-0087 Phase II study of targeting CD28 in multiple myeloma with abatecept CTLA4-Ig to overcome resistance to chemotherapy No ClinicalTrials.gov identifier reported
- 2016-Other-0570 A PROSP TISSUE COLLECTION PROTOCOL TO INVESTIGATE PREDICTIVE MODELS OF RESP TO NIVO IN COMB WITH IPI FOLLOWED BY NIVO MONOTHERAPY IN PTS WITH ADV MUCOSAL AND ACRAL LENTIGINOUS MELANOMA No ClinicalTrials.gov identifier reported
- 2016-Other-0594 A Phase II Study of Nivolumab plus Ipilimumab in Patients with Recurrent/Metastatic Salivary Glands No ClinicalTrials.gov identifier reported
- 2016-Other-0626 Radiotherapy with nivolumab and ipilimumab in patients with high-risk locally advanced SSCHN No ClinicalTrials.gov identifier reported
- 2016-Other-0685 Ipi and nivo in comb with immunoembolization for the treatment of metastatic uveal melanoma No ClinicalTrials.gov identifier reported
- 2016-S-0054 Early chronic CML No ClinicalTrials.gov identifier reported
- 2016-S-0056 St. Jude Total XVII No ClinicalTrials.gov identifier reported
- 2016-Y-0076 IntraTumor IO in vivo screening platform No ClinicalTrials.gov identifier reported
- 2016-Y-0080 A Phase 2 study of Nivolumab plus Ipilimumab in RAI refractory aggressive thyroid cancer No ClinicalTrials.gov identifier reported
- 2016-Y-0094 Phase II Trial of Nivolumab plus Ipilimumab in Patients With Renal Medullary Carcinoma No ClinicalTrials.gov identifier reported
- 2016-Y-0095 Ph2 Consolidation Immunotherapy w Nivo and Ipi or Nivo alone following Concurrent Chemoradiotherapy for Unresectable Stg IIIA/IIIB NSCLC No ClinicalTrials.gov identifier reported
- 2016-Y-0097 A ph II study to eval the safety, pharm & efficacy of entinostat in comb with nivo plus ipi in pts with rcc prev tx with nivo plus ipi No ClinicalTrials.gov identifier reported
- 20-17 No ClinicalTrials.gov identifier reported
- 2017-0039 No ClinicalTrials.gov identifier reported
- 20170625-Vesalius - CV No ClinicalTrials.gov identifier reported
- 20170625_Vesalius - CV No ClinicalTrials.gov identifier reported
- 2017-1366 No ClinicalTrials.gov identifier reported
- 2017-2753 Margolis No ClinicalTrials.gov identifier reported
- 2017-3039 Yen No ClinicalTrials.gov identifier reported
- 2017-3062 Chumsri No ClinicalTrials.gov identifier reported
- 2017-3062 - Chumsri No ClinicalTrials.gov identifier reported
- 2017 Aspire Derm A Study to Assess the Safety and Efficacy of Crisaborole 2 Ointment in Subjects With Psoriasis on the Face and Or Intertriginous Inverse Areas No ClinicalTrials.gov identifier reported
- 2017 Aspire Dermatology Comprehensive Patient Decision Aids for Hydradenitis Suppurativa No ClinicalTrials.gov identifier reported
- 2017 Aspire Dermatology Eucrisa for Atopic Dermatitismeasuring and Improving Adherence to Topical Eucrisa in Patients With Atopic Dermatitis No ClinicalTrials.gov identifier reported
- 2017 Aspire Dermatology Eucrisa for Atopic Dermatitismeasuring and Improving Adherence to Topical Eucrisa in Patients With Atopic Dermatitis No ClinicalTrials.gov identifier reported
- 2017 Aspire Dermatology Impact of Pruritus on Clinical and Biological Outcomes in Atopic Dermatitis and Bullous Pemphigoid No ClinicalTrials.gov identifier reported
- 2017 Aspire Dermatology Pilot Study Evaluating the Efficacy of A Topical Pde4 Inhibitor for Morphea No ClinicalTrials.gov identifier reported
- 2017 Aspire Dermatology Pilot Study Evaluating the Efficacy of A Topical Pde4 Inhibitor for Morphea No ClinicalTrials.gov identifier reported
- 2017 Aspire Global Endocrine Pituitary Volume in Children With Short Stature and Normal Controls the Segue to the New Gold Standard to Determining Adequate Growth Hormone Production No ClinicalTrials.gov identifier reported